Biodesix
Broomfield
About Biodesix
Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring, and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $445.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: nasdaq:BDSX
- Website: biodesix.com
- Phone: 303-417-0500
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/biodesix-15788 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.